LA
JOLLA, Calif., Nov. 7, 2024
/PRNewswire/ -- CalciMedica, Inc. (CalciMedica or the Company)
(Nasdaq: CALC), a clinical-stage biopharmaceutical company focused
on developing novel calcium release-activated calcium (CRAC)
channel inhibition therapies for acute and chronic inflammatory and
immunologic illnesses, today announced the appointment of
Stephen Bardin as Chief Financial
Officer and the planned departure of Daniel Geffken, Interim
Chief Financial Officer upon filing the Company's third quarter
financial statements. Mr. Bardin brings extensive capital raising,
corporate development, and strategic finance expertise to
CalciMedica, having most recently served as CFO of atai Life
Sciences.
"We are delighted to bring Stephen on board. He is a skilled and
experienced biotechnology executive who will be invaluable to
CalciMedica as we advance our clinical-stage pipeline," said Rachel
Leheny Ph.D., Chief Executive Officer of CalciMedica. "Stephen has
been advising us on various strategic matters for several months
and, most recently, was critical in executing our successful public
financing last week. We look forward to his many future
contributions as he now joins us full-time."
"CalciMedica has made impressive recent progress, delivering
compelling clinical data for large and underserved patient
populations," said Mr. Bardin. "The CARPO Phase 2b data in patients with acute pancreatitis
announced last month is promising and provides an optimistic
readthrough to KOURAGE, CalciMedica's Phase 2 trial in acute kidney
injury, which is expected to read out next year. I look forward to
working more closely with the team as we advance AKI in the clinic
and prepare for a Phase 3 program in AP."
Mr. Bardin most recently served as CFO of atai Life
Sciences where he played a key role in the company's investor
relations, business development, capital allocation, and financial
operations activities. Prior to that, Mr. Bardin spent nearly three
years at BridgeBio Pharma, Inc., a commercial-stage
biopharmaceutical company with a broad pipeline of development
programs, where he oversaw a broad range of finance activities and
helped raise over $2B through a
variety of financing transactions. Prior to that, Mr. Bardin held
positions focused on finance, operations, and corporate development
at Myovant Sciences, Inc., a subsidiary of Roivant at the
time. He began his career advising life sciences companies at the
Boston Consulting Group. Mr. Bardin holds an M.B.A. from the
Stanford Graduate School of Business and graduated summa cum laude
from Duke University with a B.S.E. in
Biomedical Engineering.
About CalciMedica
CalciMedica is a clinical-stage biopharmaceutical company
focused on developing novel CRAC channel inhibition therapies for
inflammatory and immunologic
diseases. CalciMedica's proprietary technology targets
the inhibition of CRAC channels to modulate the immune response and
protect against tissue cell injury, with the potential to provide
therapeutic benefits in life-threatening inflammatory and
immunologic diseases for which there are currently no approved
therapies. CalciMedica's lead product candidate Auxora™
has demonstrated positive and consistent clinical results in
multiple completed efficacy clinical
trials. CalciMedica has announced data for a Phase
2b trial (called CARPO
– NCT04681066) in patients with acute pancreatitis (AP) with
systemic inflammatory response syndrome (SIRS) and completed a
Phase 2 trial (called CARDEA – NCT04345614) in patients with
COVID pneumonia. The Company is currently conducting a Phase 2
trial (called KOURAGE – NCT06374797) in patients with acute
kidney injury (AKI) with associated acute hypoxemic respiratory
failure (AHRF) with data expected in 2025 and continuing to support
the ongoing Phase 1/2 trial (called CRSPA – NCT04195347) in
patients with asparaginase-induced pancreatic toxicity (AIPT) with
data expected in 2025. CalciMedica was founded by
scientists from Torrey Pines Therapeutics and the Harvard CBR
Institute for Biomedical Research, and is headquartered in La
Jolla, CA. For more information, please
visit www.calcimedica.com.
Forward-Looking Statements
Any statements in this
press release about future expectations, plans and prospects for
CalciMedica, including statements about CalciMedica's business
strategy; the potential benefits of Auxora for the treatment of AP,
AKI and AIPT; expected timing for the release of data from its
clinical trials; the potential
of CalciMedica's proprietary technology to provide
therapeutic benefits in other life-threatening inflammatory and
immunologic diseases; and other statements containing the words
"anticipate," "believe," "estimate," "expect," "intend," "may,"
"plan," "predict," "project," "target," "potential," "will,"
"would," "could," "should," "continue," and similar expressions,
constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by such forward-looking
statements as a result of various important factors, including:
economic, business, competitive, and/or regulatory factors
affecting the business of CalciMedica generally. Additional risks
and uncertainties that could cause actual outcomes and results to
differ materially from those contemplated by the forward-looking
statements are included under the caption "Risk Factors" in
CalciMedica's Quarterly Report on Form 10-Q for the quarter ended
June 30, 2024 and other filings
CalciMedica makes with the SEC from time to time and available at
www.sec.gov. These documents can also be accessed
on CalciMedica's web page
at ir.calcimedica.com/financials-filings/sec-filings. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. CalciMedica undertakes
no obligation to update such statements to reflect events that
occur or circumstances that exist after the date on which they were
made, except as required by law.
CalciMedica Contact:
Investors and Media
Argot Partners
Sarah Sutton/Kevin Murphy
calcimedica@argotpartners.com
(212) 600-1902
View original content to download
multimedia:https://www.prnewswire.com/news-releases/calcimedica-strengthens-leadership-team-with-appointment-of-stephen-bardin-as-chief-financial-officer-302298169.html
SOURCE CalciMedica, Inc.